FBR Capital Markets Spring In

RNS Number : 2795V

Oxford Biomedica PLC

27 May 2008

 

FOR IMMEDIATE RELEASE	27 MAY 2008

OXFORD BIOMEDICA TO PRESENT AT FBR CAPITAL MARKETS SPRING INVESTOR CONFERENCE

Oxford, UK - 27 May 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces that Dr Mike McDonald, the Company's Chief Medical Officer, will present a company update on Wednesday, 28 May 2008 at 10.30 am EDT (3.30 pm BST) at the FBR Capital Markets 12th Annual Spring Investor Conference at the Grand Hyatt New York in New York. The presentation will be webcast live and may be accessed under the investors section of the Company's website, www.oxfordbiomedica.co.uk. The presentation webcast will also be available for replay.

-Ends-

For further information, please contact:
Oxford BioMedica plc:  Professor Alan Kingsman, Chief Executive	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Communications	Tel: [phone]
Scientific/Trade Press Enquiries: Holly Griffiths/ Katja Stout/ Claire Mosley College Hill Life Sciences	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. 

The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. The lead product candidate is TroVax®, a therapeutic vaccine for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. TroVax is in Phase III development. Oxford BioMedica has three other products in clinical development, including ProSavin®, a novel gene-based treatment for Parkinson's disease, in a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 85. Oxford BioMedica has collaborations with sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. 

Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

NRAGCGDUSDDGGIR